These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 18432584

  • 1. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [Abstract] [Full Text] [Related]

  • 2. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators.
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [Abstract] [Full Text] [Related]

  • 3. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA.
    PLoS One; 2015 Jul; 10(12):e0143492. PubMed ID: 26640956
    [Abstract] [Full Text] [Related]

  • 4. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F.
    Kidney Blood Press Res; 2015 Jul; 40(3):258-65. PubMed ID: 25997572
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
    El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM.
    World J Gastroenterol; 2014 Apr 28; 20(16):4681-91. PubMed ID: 24782620
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A, Midha V, Goyal O.
    Ann Hepatol; 2014 Apr 28; 13(5):503-9. PubMed ID: 25152982
    [Abstract] [Full Text] [Related]

  • 10. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.
    Drugs; 2008 Apr 28; 68(6):791-801. PubMed ID: 18416586
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F, Dixit V, Martin P, Messa P.
    J Viral Hepat; 2011 Jul 28; 18(7):e263-9. PubMed ID: 21108701
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Aug 28; 59(2):205-12. PubMed ID: 23542346
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M, Brazilian Pegasys Cooperative Study Group.
    Braz J Infect Dis; 2006 Feb 28; 10(1):11-6. PubMed ID: 16767309
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.